Nogitecan
Brain Neoplasm
Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Jeffrey N. Bruce
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05521984CT.gov Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | — | Recruiting | — | — | — |
NCT04239092CT.gov 9-ING-41 in Pediatric Patients With Refractory Malignancies. | — | Terminated | — | — | — |
NCT01931098CT.gov Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab | — | Completed | — | — | — |
NCT00918320CT.gov Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nogitecan (this asset) | Jeffrey N. Bruce | P2 | BB · 67 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Temsirolimus | M.D. Anderson Cancer Center | P2 | BBB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Dexmedetomidine | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vorinostat | H. Lee Moffitt Cancer Center and Research Institute | P2 | BB |
| Nivolumab | InSightec | P3 | BB |
| Cyclophosphamide | Essen Biotech | P3 | BB |
| Irinotecan | NaviFUS Corporation | P3 | BB |
+41 more in the Brain Neoplasm cohort
Other indications for Nogitecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | BBB · 74 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Non-Small Cell Lung Carcinoma | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Nogitecan in Brain Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/nogitecan-brain-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →